Randomised Assessment of Treatment using Panel Assay of Cardiac markers – a trial of rapid blood testing for acute chest pain in six NHS hospitals around the UK.
To evaluate the clinical effectiveness and cost-effectiveness of the most promising point-of-care cardiac marker panel currently used in the emergency department.
Multi centre randomised controlled trial of point of care markers vs standard care in patients with acute chest pain in the Emergency Department.
Goodacre SW, Bradburn M, Cross E, et al. The Randomised Assessment of Treatment using Panel Assay of Cardiac Markers (RATPAC) trial: a randomised controlled trial of point-of-care cardiac markers in the emergency department. Heart 2011;97:190–6.
Fitzgerald P, Goodacre SW, Cross E, Dixon S: Cost-effectiveness of point-of-care biomarker assessment for suspected myocardial infarction: the randomized assessment of treatment using panel Assay of cardiac markers (RATPAC) trial. Acad Emerg Med 2011; 18(5): 488-95.
Bradburn M, Goodacre SW, Fitzgerald P, Coats T, Gray A, Hassan T, Humphrey J, Kendall J, Smith J, Collinson P; RATPAC Research Team: Interhospital variation in the RATPAC trial (Randomised Assessment of Treatment using Panel Assay of Cardiac markers). Emerg Med J 2012; 29(3): 233-8.
Goodacre S, Bradburn M, Fitzgerald P Cross E, Collinson P, Gray A and Hall AS. The RATPAC (Randomised Assessment of Treatment using Panel Assay of Cardiac markers) trial: a randomised controlled trial of point-of-care cardiac markers in the emergency department. Health Technology Assessment. (2011);15(23).
P Collinson, S Goodacre, D Gaze and A Gray. Very Early Diagnosis Of Chest Pain By Point Of Care Testing; Comparison Of The Diagnostic Efficiency Of A Panel Of Cardiac Biomarkers Compared To Troponin Measurement Alone In The Randomised Assessment Of Panel Assay Of Cardiac Markers (RATPAC) Trial. Heart. (2012);98:312-318.
Global Anticoagulant Registry in the FIELD observing treatment and outcomes in patients with treated acute Venous Thromboembolic Events in the real world
Global Anticoagulant Registry In the FIELD – Venous Thromboembolic Events
1. Ambulatory Device, Rocket Pleural vent insertion
2. Standard Treatment, Aspiration +/- chest drain
Primary Outcome Measures
To assess whether use of an ambulatory device (Rocket Pleural Vent) and treatment strategy reduces hospital stay. Total length of stay in hospital up to 30 days post randomisation. Up to 30 days post randomisation.
RAMPP trial - Randomised Controlled Trial: Pleural vent (rocket) V standard care in Primary Spontaneous Pnuemothorax